Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.

Détails

Ressource 1Télécharger: 38663923.pdf (651.82 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_AC208C4ACC61
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.
Périodique
BMJ open
Auteur⸱e⸱s
Dao K., Shechtman S., Weber-Schoendorfer C., Diav-Citrin O., Murad R.H., Berlin M., Hazan A., Richardson J.L., Eleftheriou G., Rousson V., Diezi L., Haefliger D., Simões-Wüst A.P., Addor M.C., Baud D., Lamine F., Panchaud A., Buclin T., Girardin F.R., Winterfeld U.
ISSN
2044-6055 (Electronic)
ISSN-L
2044-6055
Statut éditorial
Publié
Date de publication
24/04/2024
Peer-reviewed
Oui
Volume
14
Numéro
4
Pages
e083550
Langue
anglais
Notes
Publication types: Journal Article ; Observational Study ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are indicated for the treatment of type 2 diabetes and more recently for weight loss. The aim of this study was to assess the risks associated with GLP1-RA exposure during early pregnancy.
This multicentre, observational prospective cohort study compared pregnancy outcomes in women exposed to GLP1-RA in early pregnancy either for diabetes or obesity treatment with those in two reference groups: (1) women with diabetes exposed to at least one non-GLP1-RA antidiabetic drug during the first trimester and (2) a reference group of overweight/obese women without diabetes, between 2009 and 2022.
Data were collected from the databases of six Teratology Information Services.
This study included 168 pregnancies of women exposed to GLP1-RA during the first trimester, alongside a reference group of 156 pregnancies of women with diabetes and 163 pregnancies of overweight/obese women.
Exposure to GLP1-RA in the first trimester was not associated with a risk of major birth defects when compared with diabetes (2.6% vs 2.3%; adjusted OR, 0.98 (95% CI, 0.16 to 5.82)) or to overweight/obese (2.6% vs 3.9%; adjusted OR 0.54 (0.11 to 2.75)). For the GLP1-RA group, cumulative incidence for live births, pregnancy losses and pregnancy terminations was 59%, 23% and 18%, respectively. In the diabetes reference group, corresponding estimates were 69%, 26% and 6%, while in the overweight/obese reference group, they were 63%, 29% and 8%, respectively. Cox proportional cause-specific hazard models indicated no increased risk of pregnancy losses in the GLP1-RA versus the diabetes and the overweight/obese reference groups, in both crude and adjusted analyses.
This study offers reassurance in cases of inadvertent exposure to GLP1-RA during the first trimester of pregnancy. Due to the limited sample size, larger studies are required to validate these findings.
Mots-clé
Humans, Female, Pregnancy, Prospective Studies, Adult, Pregnancy Trimester, First, Glucagon-Like Peptide-1 Receptor/agonists, Hypoglycemic Agents/therapeutic use, Hypoglycemic Agents/adverse effects, Pregnancy Outcome/epidemiology, Obesity/epidemiology, Diabetes Mellitus, Type 2/drug therapy, Abnormalities, Drug-Induced/epidemiology, Pregnancy in Diabetics/drug therapy, Databases, Factual, Pregnancy Complications/drug therapy, Diabetes in pregnancy, Obesity, Pregnant Women, Safety
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/04/2024 8:06
Dernière modification de la notice
04/06/2024 6:46
Données d'usage